New drug data makes this French biotech stock a buy, says Jefferies

Abivax (ABVX) surged 39% on Tuesday after Jefferies upgraded the stock to buy from hold and raised its price target to $158 from $108 (implying ~18% upside from the prior close). The call cited new obefazimod ulcerative colitis data showing malignancies in treated patients were in line with normal UC rates, and that over a third of initial non-responders achieved remission after ~10 months. Jefferies noted investor overhangs were addressed, while still flagging risks around cash runway and a potential standalone commercial path. Abivax is also broadly supported by street coverage (10 of 12 analysts rate buy/strong buy per LSEG).

Analysis

The key mechanism is not the data point itself, but the removal of a tail-risk discount. ABVX is transitioning from a “safety ambiguity” story to a more normal late-stage biotech, which can lower implied financing risk and widen the set of buyers willing to underwrite the stock on clinical probability rather than litigation-style uncertainty. That usually matters more for multiple re-rating than for near-term fundamentals, so the first leg can continue even if there is no immediate commercial revenue.

The harder question is whether the move has already front-run the de-risking. A 39% one-day reprice suggests the market is now paying for a cleaner approval path, while the remaining overhang shifts to cash runway and whether the eventual launch can be financed without punitive dilution. In biotech, that second-order effect often caps upside: even good efficacy can be offset if the company must tap capital markets before the next decisive catalyst.

Competitive dynamics are favorable only if the durability signal persists. If remission continues to deepen over the next 1-3 months, ABVX can pressure valuation gaps versus other IBD developers and support a higher probability of partnership or strategic optionality. But if follow-up data stalls or safety scrutiny returns, the stock will likely mean-revert fast because the current re-rating is still narrative-driven rather than cash-flow driven.

Key Decisions for Investors

• ABVX: do not chase the gap higher; prefer adding only on a 5-10% pullback or after a multi-day consolidation, with a tight stop back below the post-breakout area. Risk/reward is better after implied volatility compresses.
• ABVX call spread: for a 1-3 month catalyst window, consider a modest-sized out-of-the-money call spread instead of common to express upside while capping dilution and headline risk. Best suited if you expect another confirming data release before financing.
• Pair trade: long ABVX / short XBI to isolate idiosyncratic de-risking from broad biotech beta. This works best if the next catalyst is data-driven rather than market-driven; cut if XBI outperforms on risk-on flows without ABVX follow-through.
• Set a financing alert: if management announces an equity raise or ATM before the next catalyst, treat it as a thesis stress test and reduce exposure. That would tell you the market has moved ahead of the balance sheet.
• Watch for failure to hold the post-upgrade breakout on volume. If ABVX gives back most of the recent move before the next data update, the market is signaling that the re-rating was fully priced and the cleaner path is not yet enough to support sustained ownership.